Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-14T18:24:23.576Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial – CORRIGENDUM

Published online by Cambridge University Press:  14 October 2024

Colleen Loo ,
Nick Glozier ,
David Barton ,
Bernhard T. Baune ,
Natalie T. Mills ,
Paul Fitzgerald ,
Paul Glue ,
Shanthi Sarma ,
Veronica Galvez-Ortiz  and
Dusan Hadzi-Pavlovic
...Show all authors
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Corrigendum
Information
The British Journal of Psychiatry , Volume 225 , Issue 2 , August 2024 , pp. 349
Check for updates
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

This article was originally published with an error in the outcome of blinding assessment results. The paper reported outcomes for the evaluation of blinding at the end of the 4-week RCT, but the data used was from the evaluation done after treatment one, rather than the end of RCT timepoint.

The errors have been rectified in the online versions of the article and linked supplementary material.

References

Loo, C, Glozier, N, Barton, D, et al. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. The British Journal of Psychiatry. 2023;223(6):533–541.CrossRefGoogle ScholarPubMed

This correction applies to the following article(s):

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial

Colleen Loo [Opens in a new window]Colleen Loo , Nick Glozier [Opens in a new window]Nick Glozier , David Barton , Bernhard T. Baune , Natalie T. Mills , Paul Fitzgerald , Paul Glue , Shanthi Sarma , Veronica Galvez-Ortiz , Dusan Hadzi-Pavlovic , Angelo Alonzo , Vanessa Dong , Donel Martin , Stevan Nikolin [Opens in a new window]Stevan Nikolin , Philip B. Mitchell [Opens in a new window]Philip B. Mitchell , Michael Berk , Gregory Carter , Maree Hackett , John Leyden , Sean Hood [Opens in a new window]Sean Hood , Andrew A. Somogyi , Kyle Lapidus , Elizabeth Stratton , Kirsten Gainsford , Deepak Garg , Nicollette L. R. Thornton [Opens in a new window]Nicollette L. R. Thornton , Célia Fourrier , Karyn Richardson , Demi Rozakis , Anish Scaria , Cathrine Mihalopoulos , Mary Lou Chatterton , William M. McDonald , Philip Boyce [Opens in a new window]Philip Boyce , Paul E. Holtzheimer , F. Andrew Kozel , Patricio Riva-Posse  and Anthony Rodgers  
Submit a response

eLetters

No eLetters have been published for this article.